Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02492815 · ClinicalTrials.gov registry record
PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 1,773
- Enrollment target
NCT02492815: Completed study, sponsored by Bristol-Myers Squibb.
NCT02492815 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,773 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02492815 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 1,773 participants
- Enrollment target
Study Summary
Observational study to evaluate the effectiveness and safety of ipilimumab, administered during the European expanded access programme (EAP) in pretreated patients with advanced (unresectable or metastatic) melanoma.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,773 participants |
| Start Date | 2013-10-31 |
| Est. Completion | 2016-04-30 |
What the finished NCT02492815 record still lists
NCT02492815 is an observational study that tracks outcomes without assigning an intervention. Its 1,773 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02492815 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02492815 about?
NCT02492815 is a clinical study titled "PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma". Observational study to evaluate the effectiveness and safety of ipilimumab, administered during the European expanded access programme (EAP) in pretreated patients with advanced (unresectable or metastatic) melanoma.
What is the current status of trial NCT02492815?
This trial is currently completed. The enrollment target is 1,773 participants. The study started on 2013-10-31. Estimated completion is 2016-04-30.
Who is sponsoring clinical trial NCT02492815?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03067181 · 1,780 participants · Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- NCT06526650 · 1,780 participants · NA
'Ai Pono Cooking Demonstrations
- NCT06239688 · 1,764 participants · NA
Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
- NCT05770570 · 1,785 participants · Phase 2
Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI